Cellectis Company
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company's portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company's products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.
%20.jpg)
Total Funding:
181 347 248
Acquisitions Number:
2
Headquarters:
Paris, France
Funding Status:
IPO
Employee Number:
51-100
Estimated Revenue:
$1M to $10M
Last Funding Type:
Post-IPO Equity
Technology:
Cell Therapy
Last Funding Date:
11.04.2018
Investors Number:
5
Founded Date:
01.12.1999
Industry:
Biotechnology